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SUMMARY 
Accurate identification of individuals at high risk of surgical site infections (SSIs) or periprosthetic 
joint infections (PJI) influences clinical decisions and development of preventive strategies. We aimed 
to determine progress in the development and validation of risk prediction models for SSI or PJI using 
a systematic review. We searched for studies that have developed or validated a risk prediction tool 
for SSI or PJI following joint replacement in MEDLINE, EMBASE, Web of Science, and Cochrane 
databases, trial registers, and reference lists of studies to September 2016. Nine studies describing 16 
risk scores for SSI or PJI were identified. The number of component variables in a risk score ranged 
from 4 to 45. The C-index ranged from 0.56 to 0.74, with only three risk scores reporting a 
discriminative ability of > 0.70. Five risk scores were validated internally. The National Healthcare 
Safety Network SSIs risk models for hip and knee arthroplasties (HPRO and KPRO) were the only 
scores to be externally validated. Except for HPRO which shows some promise for use in a clinical 
setting (based on predictive performance and external validation), none of the identified risk scores 
can be considered ready for use. Further research is urgently warranted within the field.  
 
Key words: Bone infections, Epidemiology, Risk assessment 
Systematic review registration: PROSPERO 2016: CRD42016042158 
  
3 
 
INTRODUCTION 
Surgical site infections (SSIs) which can be classified as superficial wound infections, deep wound 
infections, or periprosthetic joint infections (PJIs),[1] are uncommon but serious complications of 
total joint replacements.[2, 3] Periprosthetic joint infections can result in severe pain, functional 
deficits, and even death;[4-6] and their management is a huge financial burden to health care 
systems.[7, 8] With increasing life expectancy and a growing indication for primary joint 
replacements,[9] there will be a proportionate rise in the number of patients who will be affected by 
PJIs. An approach to tackle the increasing incidence of PJIs is to identify those people at high risk and 
offer appropriate interventions. Early and accurate identification of individuals at high risk of PJI 
influences clinical decisions and development of targeted preventive strategies, and helps to optimise 
resources required for detection of PJI.  Several factors such as characteristics of the patient, surgical 
procedure, and post-operative care, have been found to influence the risk of developing PJI,[10, 11] 
however their potential utility for PJI risk assessment remains uncertain.  
A risk score or prognostic model is a statistical equation that predicts an individual’s disease risk 
based on a combination of the values of multiple predictors or risk factors.[12] Risk prediction scores 
are ideally developed using data from long-term follow-up of large population-based cohorts of 
individuals without a history of the event of interest (SSI or PJI in this case) at baseline. The dataset is 
used to identify important predictors and the model equation is developed.[13] Using the derivation 
sample, the score’s apparent performance is evaluated in a process known as internal evaluation. The 
next stage is external validation, which examines the generalisability of the model using new data. 
Risk prediction scores first emerged in the area of cardiovascular disease (CVD) prevention and have 
been widely used globally in clinical and public health practice. Well known amongst them is the 
Framingham CVD risk score[14] (a risk score which assesses an individual’s risk of a cardiovascular 
event within 10 years), which is a commonly used algorithm in clinical practice and accepted tool in 
preventive medicine.  
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Prevention of SSIs or PJI is a high policy priority and there has been an increasing interest in the 
development of risk prediction tools for SSI or PJI over the last decade. However, unlike the 
substantial progress made in CVD prevention using risk scores, the amount of progress made in the 
area of SSIs or PJIs is uncertain. There is therefore a need for objective data on the development of 
risk scores (including their component variables), their discriminative abilities, whether they have 
been externally validated, and whether their clinical effectiveness have been assessed in well-designed 
randomized controlled trials (RCTs). In this context, using systematic review methodology, we aimed 
to (i) identify and summarise studies reporting the development of risk prediction scores for SSI or 
PJI; (ii) assess clinical variables selected for model inclusion and the predictive performance of these 
models; (iii) assess if identified models have been externally validated and their performances 
compared; (iv) assess if the impact or clinical effectiveness of these risk scores have been evaluated in 
appropriate RCTs; and (v) finally to identify gaps in the existing evidence and whether further 
research is needed in the field. 
 
METHODS 
This review was conducted using a predefined protocol, which has been registered in the PROSPERO 
prospective register of systematic reviews (CRD42016042158), and in line with PRISMA 
guidelines[15] (Supplementary Material 1). We searched MEDLINE, EMBASE, Web of Science, 
and The Cochrane Library electronic databases up to September 30, 2016. The publicly available trial 
registers ClinicalTrials.gov, UK Clinical Research Network Study Portfolio Database (UKCRN), and 
the WHO International Clinical Trials Registry Platform were also searched. The search strategy 
combined free and MeSH search terms and combination of key words relating to risk prediction (e.g., 
“predict”, “risk score”, “sensitivity”), SSI or PJI (e.g., “periprosthetic joint infection”, “deep 
infection”, “surgical site infection”), and joint replacement (e.g., “hip replacement”, “knee 
replacement”, “hip arthroplasty”, “knee arthroplasty”). No restrictions were placed on publication 
dates and only articles published in English were considered. Reference lists of retrieved articles and 
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relevant review articles identified on the topic were manually scanned for all relevant additional 
studies. Detailed description of all Materials and Methods, as well as the Literature Search Strategy 
are available in Supplementary Materials 2 and 3. 
 
RESULTS 
Study identification and selection 
Figure 1 shows the flow of studies through the review. Our literature search strategy identified 1802 
potentially relevant articles. After the initial screening of titles and abstracts, 15 articles remained for 
further evaluation. Following detailed evaluation which included full text reviews, 6 articles were 
excluded because (i) they were studies of diagnostic scores (n=2) and (ii) they were studies of risk 
scores for outcomes such as readmission, infection eradication, and treatment outcome of PJI (n=4). 
The remaining nine articles met the inclusion criteria and were included in the review.[16-24] 
 
Study characteristics and quality assessment 
Table 1 summarises characteristics of the studies in the sample. Studies were published between 2006 
and 2016, with all but one appearing in 2011 to 2016. One study was reported as a published 
conference abstract.[16] Overall, the studies involved 482,877 joint replacements, including 6968 
SSIs or PJIs. For studies that reported age data, the baseline age of participants ranged from 56 to 81 
years. The sample size of cohorts ranged from 217 to 172,055 and follow-up for infection outcomes 
ranged from 30 days to 2 years. For the assessment of infections, the majority of the studies used 
Centre for Disease Control or Infectious Diseases Society of America Criteria. Studies classified 
infection outcomes as SSI or PJI specifically. One study employed both SSI and PJI outcomes[21] 
and another study used PJI recurrence.[24] Quality assessment using PROBAST showed evidence of 
high overall risk of bias throughout the included studies. Five risk scores had unclear concern for 
overall applicability and only two scores were deemed to be usable in the targeted individuals and 
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context [the National Healthcare Safety Network (NHSN) surgical site infections risk models for hip 
and knee arthroplasties (HPRO and KPRO)][18] (Supplementary Material 4). 
 
Model description and development 
Table 2 provides details of risk scores included in eligible studies: their component predictors, 
statistical properties, measures of discrimination and/or calibration, and reports of any validation and 
performance comparisons made. A total of 16 risk scores were described in the 9 eligible studies. Five 
of these scores had separate models for hip and knee replacement patients.[18, 22, 23] Four studies 
described the development of two or more risk scores.[18, 19, 22, 23] All 16 risk scores were 
derivations of risk models on a base population and two of them were also externally validated on 
new populations.[21] Except for one study that developed the risk score based on a cohort recruited 
prospectively for the surveillance of surgical site infections (SSIs),[17] all studies used datasets 
retrospectively that had been established for different purposes. Except for the scores that were 
developed in both knee and hip replacement patients, the component predictors varied from score to 
score. However, age, sex, and type of primary surgery featured in the majority of risk scores. Except 
for one score that was mainly based on invasive data such as erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), and microbial aetiology,[24] all scores were based on data that can be 
assessed non-invasively such as demographics, anthropometrics, medical and surgical histories, and 
surgical procedures. The number of component variables in a single score ranged from 4 to 45 (n=16, 
median 19, interquartile range 6.5-32.5). Seven out of the 16 risk scores had 10 or fewer components. 
Of the 16 risk scores, 15 used regression techniques (logistic or Cox) to develop the score and one 
used a classification tree.[24]  
 
Model diagnostics 
Except for three studies (comprising of three risk scores),[16, 20, 24] the C-statistic was reported for 
13 risk scores. The C-index ranged from 0.56 to 0.74. Only three risk scores were reported to have a 
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discriminative ability of > 0.70 and these were the Baseline Mayo and 1-month-postsurgery Mayo PJI 
risk scores as reported by Berbari and colleagues[19] and HPRO which was externally validated by 
Lewallen and colleagues.[21] Calibration measures were presented for 11 risk scores (including the 
Baseline Mayo PJI risk score) and each was reported to have satisfactory model calibration. Two 
studies did not report on any measures of discrimination or calibration.[20, 24] (Table 2).[24] 
 
Model validation 
Only five of the risk scores were validated internally using resampling techniques such as 
bootstrapping and cross-validation.[17, 18, 23] These included (i) a total hip arthroplasty (THA) 
specific risk model for SSI, developed using data collected from 62 acute care hospitals within the 
Dutch surveillance network for nosocomial infections;[17] (ii) the NHSN surgical site infections risk 
models for hip and knee arthroplasties (HPRO and KPRO);[18] and (iii) Claims-based risk models for 
THA and total knee arthroplasty (TKA).[23] Only the HPRO and KPRO risk scores were externally 
validated using an independent dataset in a different study.[18] Although the HPRO score performed 
better in the external cohort compared with the internal validation cohort, the KPRO risk score 
performed much less well when tested on the external cohort compared with the internal cohort 
(Table 2). 
 
Performance comparisons 
The performance of five risk scores was compared with existing models in three studies.[17-19] 
Geubbels and colleagues compared the predictive performance of their newly developed THA 
specific risk score for SSI with the National Nosocomial Infection Surveillance system (NNIS) risk 
index [which incorporates three risk factors of equal weight namely wound contamination class, 
American Society of Anaesthesiologists (ASA) score, and duration of surgery], and reported better 
predictive performance for the new risk score (C-index: 0.64 versus 0.56; P < 0.001).[17] Mu and 
colleagues also reported statistically significantly better performances for the HPRO and KPRO risk 
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scores when compared with the traditional NHSN surgical site infection risk model, though the C-
statistics were generally low (< 0.70).[18] The baseline Mayo and 1-month-postsurgery Mayo PJI risk 
scores also performed well compared with the traditional NHSN surgical site infection risk score (C-
index: 0.72 versus 0.64; P < 0.001) and (C-index: 0.72 versus 0.63; P < 0.001) respectively.[19] Two 
studies assessed the incremental prognostic value of adding additional risk factors to their existing 
models.[21, 23] Lewallen and colleagues externally validated the HPRO and KPRO risk scores and 
reported that addition of information on morbid obesity and diabetes mellitus to each score modestly 
improved discrimination.[21] On addition of four clinical risk factors (morbid obesity, prior non-
arthroplasties on the same joint, ASA score, and operative time) to their claims-based risk models for 
THA and TKA, Maradit Kremers and colleagues reported improved performance (by C-statistics) for 
both models, though the THA model showed better performance than the TKA model.[23] There was 
however no noticeable improvement in calibration for both models. Finally, whiles there was an 
improvement in IDI for the THA score, no significant improvement was seen for the TKA score:  
0.37% (0.12% to 0.62%) and 0.09% (-0.02% to 0.21%) respectively. 
 
Clinical evaluation of risk scores 
None of the studies described the evaluation of the clinical effectiveness of a score in an intervention 
study or as part of an impact study aimed at changing patient outcomes. 
 
DISCUSSION 
Key findings 
Using systematic review methods, we have reported the first overview of available risk assessment 
scores for SSI or PJI following joint replacement. Based on established quality criteria for risk 
scores,[25, 26] none of the risk scores in our review were judged to be promising for use in clinical 
settings or public health practice, except for the NHSN surgical site infection risk model for hip 
arthroplasties (HPRO). The HPRO is a procedure-specific risk score which was adapted from the 
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traditional NHSN risk index using NHSN data and its purpose is for predicting SSI or PJI within one 
year of hip replacement.[18] The HPRO was found to perform better than the traditional NHSN risk 
index and external validation in an independent cohort showed high discriminative ability.[21] The 
HPRO also showed higher accuracy for predicting PJI compared with SSI. The data also show that 
risk prediction models for SSI or PJI have only been developed over the last five years. Of the 16 risk 
scores identified, only seven had 10 or few components included in the final score, with a number of 
scores having between 30 to 45 components. Although risk scores that had appropriate statistics 
reported exhibited good calibration (11 risk scores), only three risk scores were reported to have a 
discriminative ability of > 0.70.  Of all 16 risk scores, HPRO and KPRO were the only risk scores 
externally validated in an independent population. Quality assessment of the risk scores’ development 
and validation criteria showed all scores to have a high risk of bias. This was mainly due to the 
methodology used in assessment of predictors and outcomes, inappropriate handling of missing data, 
and lack of external validation.  
 
Explanations and implications of findings 
Our findings highlight the limited evidence available on appropriate risk scores for predicting SSI or 
PJI after joint replacement. Given the absence of an ideal risk score which can be used in a routine 
clinical setting, it appears that the potential value of risk scores in preventing SSI or PJI may have 
been underestimated in orthopaedic practice.  The findings also highlight the use of poor methodology 
in the development of some of these risk scores. Although cross-sectional study designs were not 
included, the included studies were not free from bias and confounding. The majority of the designs 
were based on retrospective cohorts instead of prospective cohort designs, which are ideal for risk 
score modelling as predictor information can be ascertained blindly in relation to the outcome or 
disease.[13]  None of the risk scores was developed in a cohort recruited for this sole purpose, which 
introduced an inherent selection bias. A key methodological issue was the absence of clear and 
detailed reporting of the treatment of missing data in all studies, which is of utmost importance prior 
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to the development of risk scores.[12] Included studies used complete case analysis in the presence of 
missing data, which does not represent the entire population and reduces the sample size.[13] It has 
been shown that risk scores that use multiple imputation, produce more valid results and have better 
discrimination than tools that ignore such additional analyses.[27] There were also concerns with 
usability of the risk scores, as the majority of the risk scores had more than 10 variables. It is 
recognized that the simplicity of the model is an important criteria for developing clinically useful risk 
scores.[28, 29] Evidence suggests that complex models are more likely to provide overoptimistic 
predictions, especially when extensive variable selection has been performed.[30]  Only five of the 
risk scores were validated internally using resampling methods, which are techniques which give a 
good indication of how optimistic the risk score may be.[31] Although internal validation is helpful, it 
cannot provide information on the model’s performance elsewhere or its generalisability. Before a 
risk prediction tool can be used in clinical practice or in real world settings, evaluation of its 
generalisability (or transportability) requires data from elsewhere - also known as external 
validation.[12] However, only two risk scores were externally validated in our sample.[21] Finally, 
none of the risk scores was reported to have been used in an impact study aimed at changing patient 
outcomes. Before a risk score can be implemented, a vital criterion that needs to be fulfilled is its 
impact on clinical practice.[12] Among the identified risk scores, only the HPRO was found to be 
potentially promising for use in a clinical setting. However, it cannot be considered ready for use as 
its clinical effectiveness is still yet to be evaluated. The unavailability of appropriate existing risk 
scores for use in the clinical setting is extremely concerning. To add to this challenge is the lack of 
established uniform criteria for the diagnosis of infection especially PJI, which actually makes it 
difficult to conduct diagnostic or risk prediction studies for infection. Although hip and knee 
replacements are successful elective procedures, with SSIs or PJIs being rare complications of these 
procedures;[3, 32] the incidence of these infections will increase in conjunction with growing 
healthcare burden due to osteoarthritis[33] and a predicted large rise in the numbers of arthroplasty 
procedures.[34, 35] To meet this challenge, there should be a clinical drive towards identification of 
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individuals at high risk of SSIs or PJIs using risk prediction engines. The current findings should 
stimulate research groups to develop and evaluate appropriate infection outcome specific risk 
prediction algorithms using robust methodology. The clinical effectiveness of the HPRO also needs to 
be evaluated before it is implemented. Within our 5 year INFection ORthopaedic Management 
(INFORM) Programme, the aim is to develop and establish optimum strategies for the prevention and 
treatment of PJIs within the UK National Health System,[36] and which may include the development 
of appropriate risk prediction engines when the data allows. 
 
Study strengths and limitations 
To our knowledge, this is the first systematic review to identify limited progress in the development 
and validation of risk prediction models for SSI or PJI following joint replacement, using robust 
systematic methodology. It is also the first review to assess the validity of existing risk scores based 
on risk of bias and applicability. Our search strategy was comprehensive and spanned multiple 
databases, making it unlikely that any relevant study was missed. There was variation in the definition 
of SSIs in the included studies, which did not allow for a head-to-head comparison of risk scores 
across studies. We were unable to harmonise data from contributing studies to perform a quantitative 
analysis, due to the heterogeneity in study designs and populations, predictors used, model types, and 
measures reported. Even though we tried to present the data as robustly as possible using established 
criteria, our conclusions might be limited due to the quality of published research and the large 
variability across study characteristics and methodologies.  
 
CONCLUSION 
In conclusion, available risk scores to predict SSI or PJI have been developed using poor methodology 
and have several limitations. The majority of these risk scores have not been externally validated and 
are not ideal for use in clinical settings. The HPRO is the only risk prediction tool identified to show 
some promise for use in a clinical setting (based on its predictive performance and having some 
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external validation); however, it needs further validation using new data and its clinical effectiveness 
should be evaluated using a RCT design. A potentially effective way of tackling the increasing 
incidence of SSIs is early and accurate identification of individuals at high risk using established risk 
prediction scores, an approach which has been very effective in the area of CVD prevention. Further 
research is urgently warranted within the field to develop and test appropriate outcome specific risk 
prediction tools.  
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Figure legends 
 
Figure 1. PRISMA flow diagram 
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